Aetion

Global regulations like GDPR, HIPAA, Quebec’s Law 25, and the European Health Data Space (EHDS) are influencing how real-world data (RWD) is accessed, transferred, and used. In our new blog, authors Lucy Mosquera (Sr. Director, Generate Operations and Data Science) and Natalie Schibell, MPH ? (VP, Market Strategy & Communications) demonstrate how proper de-identification can ensure compliance with GDPR, HIPAA, and emerging frameworks like EHDS while also unlocking critical business advantages from data commercialization to AI model training. Learn how Aetion? Generate delivers scientifically validated de-identification now on the Aetion Evidence Hub: https://hubs.li/Q03bLgNK0

Is your clinical trial struggling to recruit? Patient recruitment shortfalls are among the most significant challenges in clinical research, often leading to underpowered studies, increased patient risk, and regulatory delays. Join us on March 19 for a live webinar showcasing groundbreaking new research on how AI-driven generative models can be used to simulate patient cohorts to bridge enrollment challenges and rescue poorly recruiting trials. Featured speakers: - Lucy Mosquera, Senior Director, Generate Operations & Data Science, Aetion - Dr. Samer El Kababji, Associate Scientist, CHEO RI - Dr. Khaled El Emam, Professor, University of Ottawa Register now to gain insights from leading clinical research and data science experts. Register here: https://hubs.li/Q03bvFN20 #ClinicalTrials #RWE #GenerativeModels #AIinHealthcare

#RealWorldEvidence (RWE) was a hot topic at #HIMSS25, appearing in more than 50 sessions. We love to see RWE take center stage because we know it’s a powerful tool we can leverage across the healthcare industry, from optimizing drug development to accelerating regulatory decision-making, and ensuring that the right treatments reach the right patients at the right time. At Aetion we’re aligned with HIMSS 2025’s theme, “creating tomorrow’s health,” through our commitment to improve patient outcomes with data science-driven technology. See how we’re delivering RWE for better healthcare decision-making: https://hubs.li/Q03bjNlb0

At Aetion, we've built our platform to work with any data model while maintaining scientific rigor. Whether you're using OMOP, proprietary structures, or specialized datasets, we’re able to transform your #RWD into trusted evidence that meets regulatory, payer, and commercial standards. Learn how we deliver interoperability without sacrificing analytic integrity in a new blog, now available on the Aetion Evidence Hub: https://hubs.li/Q039Wsqv0

Our Product and Science teams here at Aetion work hand-in-hand to ensure our solutions are not just industry-leading but scientifically rigorous. In our new blog series, Behind the Evidence: Conversations at the Intersection of Product and Science, we spotlight the A-teamers at the heart of this collaboration. For our first Q&A, we sat down with Brenna Kirk, Associate Director, Science, to talk about her journey at Aetion, her move to our Barcelona Tech Hub, and how she helps customers maximize the value of Aetion? Substantiate and Discover. Check out the full Q&A here: https://hubs.li/Q039qKC30

Traditional data sources often miss the complex clinical and biological nuances of inflammatory bowel disease (IBD). Partnering with the Crohn's & Colitis Foundation and IBD Plexus, we’ve developed a Crohn's disease progression score to better understand disease progression, define patient subgroups, and optimize treatment strategies. Read our full blog to discover how Aetion and IBD Plexus are reshaping the future of IBD drug development: https://hubs.li/Q0391Bmy0

In our newest blog, Natalie Schibell, MPH ? (VP, Market Strategy & Communications) and Pippa Hodgkins (Product Manager) explore how the Population Exploration tool within Aetion? Substantiate offers an interactive approach to uncover key demographic, treatment, and disease patterns at scale. Whether refining eligibility criteria or identifying subpopulations, the Population Exploration tool enables researchers to make informed, data-driven decisions. Check out the full blog on the Aetion Evidence Hub to learn more: https://hubs.li/Q038zpTN0

While randomized controlled trials remain the gold standard for efficacy, they don't tell the complete story. #RWE provides crucial insights into how devices perform across diverse patient populations in everyday clinical settings. In our newest blog on the Aetion Evidence Hub, we explore how regulatory agencies are increasingly incorporating RWE alongside traditional clinical data, as well as the critical role that National Evaluation System for health Technology Coordinating Center (NESTcc) plays in establishing methodological standards through their Medical Device RWE Marketplace. Check out the full blog to learn how Aetion collaborates with NEST to help manufacturers generate regulatory-grade evidence: https://hubs.li/Q038nYxw0 #MedicalDevices #RealWorldEvidence

Aetion is proud to be an inaugural member of the ISPOR—The Professional Society for Health Economics and Outcomes Research new Corporate Partner Program! This initiative strengthens our commitment to advancing real-world evidence (#RWE) for #HEOR research and beyond to improve decision-making in healthcare. At Aetion, we believe in the power of decision-grade RWE to drive better health outcomes. Alongside ISPOR and our fellow partners, we look forward to shaping the future of healthcare decision-making. Learn more about the ISPOR Corporate Partner Program here: https://hubs.li/Q038bCvX0

We are pleased to announce that Aetion has partnered with the Crohn's & Colitis Foundation as a preferred analytics partner for their IBD Plexus? Research Program. We're joining forces to accelerate #IBD research by applying our real-world evidence technology to the world's most comprehensive collection of IBD patient data and biosamples. Learn more about our partnership here: https://hubs.li/Q037wPxj0 #RealWorldEvidence #PatientCenteredResearch #IBDResearch